Abstract:Abstract Prostaglandin E2 (PGE2), a major cyclooxygenase-2 (COX-2) product, is highly secreted by the osteoblast lineage in the subchondral bone tissue of osteoarthritis (OA) patients. However, NSAIDs, including COX-2 inhibitors, have severe side effects during OA treatment. Therefore, the identification of novel drug targets of PGE2 signaling in OA progression is urgently needed. Osteoclasts play a critical role in subchondral bone homeostasis and OA-related pain. However, the mechanisms by which PGE2 regulates osteoclast function and subsequently subchondral bone homeostasis are largely unknown. Here, we show that PGE2 acts via EP4 receptors on osteoclasts during the progression of OA and OA-related pain. Our data show that while PGE2 mediates migration and osteoclastogenesis via its EP2 and EP4 receptors, tissue-specific knockout of only the EP4 receptor in osteoclasts ( EP4 LysM ) reduced disease progression and osteophyte formation in a murine model of OA. Furthermore, OA-related pain was alleviated in the EP4 LysM mice, with reduced Netrin-1 secretion and CGRP-positive sensory innervation of the subchondral bone. The expression of platelet-derived growth factor-BB (PDGF-BB) was also lower in the EP4 LysM mice, which resulted in reduced type H blood vessel formation in subchondral bone. Importantly, we identified a novel potent EP4 antagonist, HL-43, which showed in vitro and in vivo effects consistent with those observed in the EP4 LysM mice. Finally, we showed that the Gαs/PI3K/AKT/MAPK signaling pathway is downstream of EP4 activation via PGE2 in osteoclasts. Together, our data demonstrate that PGE2/EP4 signaling in osteoclasts mediates angiogenesis and sensory neuron innervation in subchondral bone, promoting OA progression and pain, and that inhibition of EP4 with HL-43 has therapeutic potential in OA.

Revisiting prostaglandin E2: A promising therapeutic target for osteoarthritis.

Osteoarthritis Versus Psoriasis Arthritis: Physiopathology, Cellular Signaling, and Therapeutic Strategies

PGE2 activates EP4 in subchondral bone osteoclasts to regulate osteoarthritis

PGE2/EP4 skeleton interoception activity reduces vertebral endplate porosity and spinal pain with low-dose celecoxib

Current understanding of osteoarthritis pathogenesis and relevant new approaches

G Protein-Coupled Receptors in Osteoarthritis

An Update of Microsomal Prostaglandin E Synthase-1 and PGE2Receptors in Cardiovascular Health and Diseases

New therapeutic strategies in osteoarthritis

Osteoarthritis: pathogenic signaling pathways and therapeutic targets

Molecular Mechanisms and Therapeutic Roles

Emerging pharmaceutical therapeutics and delivery technologies for osteoarthritis therapy

Osteoarthritis: a narrative review of molecular approaches to disease management

Small molecule inhibitors of osteoarthritis: Current development and future perspective

Pharmacotherapy for osteoarthritis-related pain: current and emerging therapies

Perlecan: Roles in osteoarthritis and potential treating target

Advancements in Inflammation Control and Cartilage Regeneration

The Organ-Joint Axes in Osteoarthritis: Significant Pathogenesis and Therapeutic Targets

Glycolysis: an emerging regulator of osteoarthritis

Current Strategies for the Treatment of Early Stage Osteoarthritis

Ellagic acid improves osteoarthritis by inhibiting PGE2 production in M1 macrophages via targeting PTGS2

Effect of Dietary Polyphenols on Osteoarthritis—Molecular Mechanisms